Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates modified coconut pomace fiber reduces hyperglycemia in diabetic rats, highlighting dietary fiber processing for metabolic disease management.
Dietary interventions for type 2 diabetes (T2DM) remain challenging. Insoluble dietary fiber (IDF) has gained attention for modulating gut microbiota and metabolic homeostasis. This study investigated the hypoglycemic effects of coconut pomace IDF before and after modification by ultrafine grinding combined with plasma-activated water treatment in a T2DM rat model. Modified coconut pomace fiber (UPCPF) ameliorated hyperglycemia, improved insulin sensitivity, and alleviated hepatic metabolic dysfunction. These effects were associated with remodeling of gut microbiota, particularly enrichment of Akkermansia and butyrate-producing bacteria, with increased fecal butyrate. Consistently, the expression of intestinal FFAR2, GCG, and PCSK1 was upregulated, resulting in enhanced GLP-1 secretion. Further analyses indicated AMPK activation, suppressed gluconeogenesis, and improved lipid metabolism. These findings indicate that UPCPF exerts metabolic benefits through modulation of the gut microbiota, increased butyrate production, and activation of AMPK signaling, providing a theoretical basis for the application of modified dietary fiber in metabolic disease management.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: